Analyst Price Targets — ACH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 22, 2026 7:17 pm | Kevin Caliendo | UBS | $3.00 | $2.61 | TheFly | Accendra Health price target lowered to $3 from $4 at UBS |
| January 6, 2026 2:32 pm | Eric Coldwell | Robert W. Baird | $5.00 | $9.04 | TheFly | Accendra Health price target lowered to $5 from $7 at Baird |
| November 3, 2025 9:06 am | Kevin Caliendo | UBS | $4.00 | $3.97 | StreetInsider | UBS Downgrades Owens & Minor (OMI) to Neutral |
| August 13, 2025 9:40 am | Kevin Caliendo | UBS | $7.00 | $5.47 | TheFly | Owens & Minor price target lowered to $7 from $13 at UBS |
| August 11, 2025 7:11 am | Michael Minchak | J.P. Morgan | $10.00 | $7.09 | Benzinga | Top Wall Street Forecasters Revamp Owens & Minor Expectations Ahead Of Q2 Earnings |
| August 8, 2025 8:56 am | Eric Coldwell | Robert W. Baird | $10.00 | $7.09 | TheFly | Owens & Minor upgraded to Outperform from Neutral at Baird |
| November 5, 2024 11:51 am | Eric Coldwell | Robert W. Baird | $14.00 | $11.80 | StreetInsider | Owens & Minor (OMI) PT Lowered to $14 at Baird |
| September 23, 2024 6:53 am | Eric Coldwell | Robert W. Baird | $19.00 | $16.08 | StreetInsider | Baird Reiterates Neutral Rating on Owens & Minor (OMI) |
| June 25, 2024 8:57 am | Michael Cherny | Leerink Partners | $17.00 | $15.00 | TheFly | Owens & Minor price target lowered to $17 from $21 at Leerink |
| June 25, 2024 6:42 am | Eric Coldwell | Robert W. Baird | $20.00 | $16.17 | TheFly | Owens & Minor price target lowered to $20 from $24 at Baird |
Latest News for ACH
Investors need to pay close attention to Accendra Health stock based on the movements in the options market lately.
Preferred Partner status highlights Alkami's commitment to advancing the ACH Network PLANO, Texas, March 3, 2026 /PRNewswire/ -- Alkami Technology, Inc. (Nasdaq: ALKT) ("Alkami"), a digital sales and service platform provider for financial institutions in the U.S., today announced it is a Nacha Preferred Partner, reinforcing Alkami's commitment to delivering secure, compliant, and modern Automated Clearing House…
Accendra Health is upgraded to "Buy" after severe underperformance, trading at just 2x 2027 free cash flow. ACH faces significant margin pressure and a challenging balance sheet, with net leverage expected at 4.9-5x by end-2026. 2026 is likely a trough year due to a major contract loss; growth is expected to resume in 2027, aided by UnitedHealth volumes.
Accendra Health, Inc. (ACH) Q4 2025 Earnings Call Transcript
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) today reported financial results for the fourth quarter ended December 31, 2025. Unless otherwise noted, the results herein reflect the Company's continuing operations, which primarily represent what was previously the Patient Direct segment and certain functional operations. “We ended the fourth quarter with the completion of the sale of the Products…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ACH.
U.S. House Trading
No House trades found for ACH.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.